Since 2002, Lilly Ventures has
focused its investments in
great companies with
compelling life science
innovations that have the
potential to create a
pipeline of life-changing
medicines. We partner actively
with our portfolio company
management teams and
provide intellectual, as
well as financial, resources
to accelerate the path to
success.
Our collaborative partnership
leverages the collective
experience, deep expertise,
and networks of our
investment professionals for
the benefit of our portfolio
companies.
Symic Bio Appoints Hicham Alaoui, Ph.D., as Senior Vice President of Discovery Biology
view full storyNovaQuest Capital Management to Acquire Viamet Pharmaceuticals and the VT-1161 Antifungal Program
view full storyProtagonist Therapeutics Announces Final Phase 1 Study Results with Novel Hepcidin Mimetic, PTG-300
view full storySutro Antibody Effectively Targets CD74 in Lymphoma & Multiple Myeloma Preclinical Studies
view full storyAileron Therapeutics Presents New Data on ALRN-6924 in Oral Presentations at 2017 American Society of Hematology Meeting
view full storyAeglea BioTherapeutics Doses First Pediatric Patient with Arginase 1 Deficiency in its Phase 1/2 Trial with Pegzilarginase (AEB1102)
view full storyProtagonist Therapeutics Initiates Phase 1 Trial of Oral Peptide IL-23 Receptor Antagonist, PTG-200
view full storySymic Bio Appoints Wayne Froland, Ph.D., as Executive Vice President of Technical Operations
view full storyHydra Biosciences TRPC 4/5 Inhibitor now investigated in clinic for Central Nervous System Disorders
view full storyAeglea BioTherapeutics to Present Preclinical Data at 2017 Society for Immunotherapy of Cancer (SITC) Annual Meeting
view full storySymic Bio Announces Results from the Phase 1/2 SHIELD Trial of SB-030 in Peripheral Vascular Disease
view full storyAileron Therapeutics Announces Oral Presentations on Lead Product Candidate ALRN-6924 at the 59th American Society of Hematology Annual Meeting
view full storyKymera Therapeutics Announces Series A to Advance Novel Therapeutic Modality and Develop Innovative Therapies
view full storyViamet to Present Data Demonstrating the Efficacy and Safety of VT-1161 for the Treatment of Recurrent Vulvovaginal Candidiasis at ISIDOG Congress 2017
view full storyEsanex Announces First Patient Dosed in an Open-Label Study of SNX-5422 in Chronic Lymphocytic Leukemia
view full storyAeglea BioTherapeutics Announces Clinical Collaboration with Merck to Evaluate the Combination of Aeglea’s AEB1102 (pegzilarginase) with Merck’s KEYTRUDA® (pembrolizumab) for the Treatment of Small Cell Lung Cancer
view full storySutro Marks Two Drug Development Milestones
view full storyProtagonist Therapeutics Prices Public Offering of Common Stock
view full storyNimbus Therapeutics and Celgene Enter Long-Term Strategic Immunology Alliance to Develop Programs for Patients with Autoimmune Disorders
view full storyProtagonist Therapeutics Announces Preliminary Phase 1 Study Results with Novel Hepcidin Mimetic, PTG-300
view full storyCavion Announces First Patient Enrolled in Its Multi-Center Phase 2 Clinical Trial in Essential Tremor
view full storyAeglea BioTherapeutics Doses Two Patients in Repeat Dose Part of Phase 1/2 Clinical Trial for the Treatment of Arginase 1 Deficiency
view full storyCelgene Corporation Exercised Option to Extend Strategic Collaboration Scope and Term with Forma Therapeutics
view full storyCoherus Biosciences Announces Positive Topline Results for Clinical Pharmacokinetic Bioequivalence Study for CHS-1420
view full storyProtagonist Therapeutics Announces Closing of Janssen License and Collaboration Agreement for PTG-200 and Receipt of $50 Million Payment
view full storyAileron Therapeutics Announces Presentation of Preclinical Data with ALRN-6924 at the International Society of Experimental Hematology Annual Scientific Meeting
view full storySymic Bio Enrolls First Patient in MODIFY2 Phase 2 Trial of SB-061 for theTreatment of Osteoarthritis
view full storyCoherus Secures Private Placement from Temasek
view full storyCavion Appoints Spyridon Papapetropoulos, M.D., Ph.D
view full storyPhase 2b Results of Viamet’s Oral VT-1161 for the Treatment of Recurrent Vulvovaginal Candidiasis Presented at IDSOG Annual Meeting
view full storySutro & Celgene to Refocus 2014 Immuno-Oncology Collaboration on Four Programs
view full storyData on VT-1161 for the Treatment of RVVC to be Presented at the Infectious Diseases Society for Obstetrics and Gynecology Annual Meeting
view full storyViamet to Present Data on VT-1161 for the Treatment of Onychomycosis at the American Podiatric Medical Association Annual Meeting
view full storyAeglea BioTherapeutics Announces Leadership Change
view full storyNew Evidence of Sutro ADC’s Potency in Human Tumor Xenografts.
view full storyAeglea BioTherapeutics Appoints James Wooldridge, M.D. as Chief Medical Officer
view full storySymic Bio Appoints Matrix Biology Researcher and Professor Glenn Prestwich as Executive Vice President of Chemistry
view full storyAileron Therapeutics Announces Pricing of Initial Public Offering
view full storyInnocrin Pharmaceuticals, Inc. Granted SME Status Designation by the European Medicines Agency
view full storySurface Oncology Expands Scientific Advisory Board with the Addition of Leading Clinical and Translational Cancer Immunotherapy Experts
view full storyCoherus Biosciences receives complete response letter from FDA for its biologics license application for CHS-1701 (pegfilgrastim biosimilar candidate)
view full storyViamet’s VT-1598 Demonstrates Potent Activity Against Candida auris and Other Life-Threatening Fungal Species
view full storyViamet Presents Phase 2b Results Demonstrating Unprecedented Efficacy of Oral VT-1161 in the Treatment of Recurrent Vulvovaginal Candidiasis
view full storyAnti-tumor Activity Observed in Phase 1 Trial of Novel P53-Targeting Drug ALRN-6924
view full storyProtagonist Therapeutics Enters into Worldwide Agreement with Janssen to Co-Develop and Commercialize PTG-200 for Inflammatory Bowel Disease
view full storyProtagonist Therapeutics Initiates Phase 1 Study with Novel Hepcidin Mimetic, PTG-300
view full storyAeglea BioTherapeutics Provides AEB1102 Program and Corporate Update
view full storySymic Bio Secures $30 Million Series B Financing and Provides SB-030 Program Update
view full storySymic Bio Announces Results from MODIFY-OA Trial of SB-061 for the Treatment of Osteoarthritis of the Knee
view full storyCoherus Biosciences prevails in ‘135 IPR decision
view full storyProtagonist Therapeutics Announces PTG-200 Data Accepted for Oral Presentation at Digestive Diseases Week
view full storyFORMA Therapeutics delivers two key objectives in collaboration with Celgene Corporation to advance protein homeostasis medicines to benefit patients.
view full storyInnocrin Appoints Fred Eschelman as CEO and is Granted Fast Track for Seviteronel for Cancer Treatment
view full storySutro ADC Targeting CD74 Eradicates BCell Hematologic Malignancy, Prolongs Survival in Tumor Models
view full story